Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Overview
Date Founded

1989

Headquarters

50 NORTHERN AVE., BOSTON, MA, 02210

Type of Company

Public

Employees (Worldwide)

3,000

Industries

Pharmaceuticals
Biotechnology

Company Description

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Contact Data
Trying to get in touch with decision makers at Vertex Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

Executive Chairman

Executive Vice President & Chief Financial Officer

Chief Commercial Officer & Executive Vice President

Executive Vice President, Global Research & Chief Scientific Officer

Senior Vice President & Chief Regulatory Officer

Senior Vice President & Chief Communications Officer

Chief Medical Officer

Senior Vice President & Chief Human Resources Officer

Paths to Vertex Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Vertex Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Price Associates uses a complex and multifaceted approach to investment analysis and asset management decisions. They integrate ESG factors into their investment research process. The firm focuses on the ESG factors they consider most likely to have a material impact on the performance of securities in client accounts. Price Associates also focuses on their analytical process on three areas of research: the industry, the contracts issued, and the creditworthiness of each individual issuer.

Details Hidden

FMR may use a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. They may also use general macro-economic analysis as a component of its security analysis methods. In addition to relying on public financial statement information, the firm may use extensive corporate visits and interviews with issuer management teams in conducting research. When it comes to the management of the client assets according to the investment objectives, FMR may use a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR’s or its affiliates’ central funds. They may also engage in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

CWI employs a long-term, value-oriented global investment approach and a multiple portfolio manager system that combines teamwork and individual accountability. The firm utilizes fundamental research to gather in-depth information on markets and companies around the world. They also employ a security-by-security approach to portfolio construction and emphasize long-term investments. Their strategies focus on determining the difference between the fundamental value of a company and its price in the marketplace. CWI offers a wide variety of equity, fixed-income and balanced investment strategies. Their strategies are categorized as global, multi-regional and regional investment strategies.

Recent Transactions
Details Hidden

Vertex Pharmaceuticals, Inc. purchases Exonics Therapeutics, Inc. from The Column Group LLC, CureDuchenne Ventures LLC

Details Hidden

Vertex Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Vertex Pharmaceuticals, Inc. purchases ViroChem Pharma, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onVertex Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onVertex Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onVertex Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onVertex Pharmaceuticals, Inc. issued USD Common Stock

Professional

Advised onVertex Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onVertex Pharmaceuticals, Inc. purchases ViroChem Pharma, Inc.

Advisors & Consultants
Advisor

Executive Vice Chair at Cushman & Wakefield of Massachusetts, Inc.

Advisor

Partner at Centerview Partners LLC

Advisor

Chief Financial Officer at Oxurion NV

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Walgreens Boots Alliance, Inc. engages in the provision of drug store services. The company operates through the following segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment engages in pharmacy-led health and beauty retail businesses, which sells its products under brand names Walgreens and Duane Reade. The Retail Pharmacy International segment offers retail stores, which sells products of brands No7, Boots Pharmaceuticals, Botanics, Liz Earle, and Soap & Glory. The Pharmaceutical Wholesale segment supplies medicines, other healthcare products and related services to pharmacies, doctors, health centers, and hospitals. The company was founded in 1901 and is headquartered in Deerfield, IL.

Cigna Corp. is a global health service company, which is dedicated to improving the health, well-being and peace of mind. Its products and services include an integrated suite of health services such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits and other related products including group life, accident and disability insurance.

Key Stats and Financials As of 2019
Market Capitalization
$70.3B
Total Enterprise Value
$53.9B
Earnings Per Share
$4.51
Revenue
$4.13B
Net Profit
$1.18B
EBITDA
$1.28B
EBITDAMargin
30.9%
Total Equity
$6.09B
Enterprise Value / Sales
13.06x
TEVNet Income
45.83x
Debt TEV
0.01x
Total Debt
$673M
Enterprise Value EBITDAOperating
42.18x
Five Year Compounded Annual Growth Rate Of Revenue
48.06%
Three Year Compounded Annual Growth Rate Of Revenue
34.38%
Non-Profit Donations & Grants
$100K - $1M
2019
$5,000 - $10K
2018
$25K - $50K
2018
Investments
Details Hidden

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Details Hidden

Genomics Plc develops research and experimental development on biotechnology. It develops and applies cutting edge analysis and algorithms to database of genomic and phenotypic data to uncover the relationships between genetic variation and human disease. The company was founded by Peter Donnely, Gil McVean, Chris Spencer and Gerton Lunter on January 10, 2004 and is headquartered in Oxford, the United Kingdom.

Details Hidden

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Suppliers
Diversified Healthcare Trust Trusts & Funds | Newton, MA

Diversified Healthcare Trust is a real estate investment trust, which engages in the ownership of senior living communities, medical office buildings, and wellness centers. It operates through the following segments: Office Portfolio, Senior Housing Operating Portfolio (SHOP), and Non-Segment. The Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants. The SHOP segment manages senior living communities that offers short term and long term residential care, and other services for residents where it pay fees to the operator to manage the communities for its account. The company was founded on December 16, 1998 and is headquartered in Newton, MA.

CRISPR Therapeutics AG Medical Support Services | Zug, Che

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Brooks Automation, Inc. Appliances & Electronics | Chemsford, MA

Brooks is a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies, and breadth of global services provide customers speed to market, high uptime, and rapid response, which equate to superior value in their mission-critical environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market. Through product development initiatives and strategic acquisition, we have expanded our reach to meet the needs of customers in the life sciences industry, analytical and research fields, and clean energy markets. When optimal productivity and high availability are factors for success, customers across the globe turn to Brooks. Brooks is a public company listed on the NASDAQ stock exchange under the symbol BRKS

Competitors
AbbVie, Inc. Pharmaceuticals - North Chicago, IL

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

Proteostasis Therapeutics, Inc. Biotechnology - Cambridge, MA

Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.

Translate Bio, Inc. Biotechnology - Lexington, MA

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

Awards & Honors
Rank #11
2014
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Vertex Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Vertex Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Vertex Pharmaceuticals, Inc..